Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples

被引：27

作者：

Schnell, T ^{[1
]}

Schmidt, B ^{[1
]}

Moschik, G ^{[1
]}

Thein, C ^{[1
]}

Paatz, C ^{[1
]}

Korn, K ^{[1
]}

Walter, H ^{[1
]}

机构：

[1] Univ Erlangen Nurnberg, German Natl Reference Ctr Retroviruses, Inst Clin & Mol Virol, Erlangen, Germany

来源：

AIDS | 2003年 / 17卷 / 08期

关键词：

D O I：

10.1097/00002030-200305230-00021

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A panel of 245 clinical samples with known treatment histories was retrospectively evaluated for cross-resistance to new protease inhibitors (PI). Samples with resistance to previously approved PI displayed high cross-resistance to atazanavir, whereas cross-resistance to amprenavir was considerably lower. A similar cross-resistance profile was observed for lopinavir, if a higher cut-off for resistance (9.5-fold) was applied. The enhanced efficacy of boosted PI is discussed with respect to clinically relevant cut-offs for drug resistance.

引用

页码：1258 / 1261

页数：4

共 14 条

[1] Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients [J].

Benson, CA ;

Deeks, SG ;

Brun, SC ;

Gulick, RM ;

Eron, JJ ;

Kessler, HA ;

Murphy, RL ;

Hicks, C ;

King, M ;

Wheeler, D ;

Feinberg, J ;

Stryker, R ;

Sax, PE ;

Riddler, S ;

Thompson, M ;

Real, K ;

Hsu, A ;

Kempf, D ;

Japour, AJ ;

Sun, E .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (05) :599-607

[2]

Chakraborty B, 2002, ANTIVIR THER, V7, pS62

[3]

Colonno RJ, 2002, ANTIVIR THER, V7, pS6

[4] Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir [J].

Duval, X ;

Lamotte, C ;

Race, E ;

Descamps, D ;

Damond, F ;

Clavel, F ;

Leport, C ;

Peytavin, G ;

Vilde, JL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :570-574

[5] In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632 [J].

Gong, YF ;

Robinson, BS ;

Rose, RE ;

Deminie, C ;

Spicer, TP ;

Stock, D ;

Colonno, RJ ;

Lin, PF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2319-2326

[6]

HAAS DW, 2002, 9 C RETR OPP INF FEB

[7] Dual vs single protease inhibitor therapy following antiretroviral treatment failure - A randomized trial [J].

Hammer, SM ;

Vaida, F ;

Bennett, KK ;

Holohan, MK ;

Sheiner, L ;

Eron, JJ ;

Wheat, LJ ;

Mitsuyasu, RT ;

Gulick, RM ;

Valentine, FT ;

Aberg, JA ;

Rogers, MD ;

Karol, CN ;

Saah, AJ ;

Lewis, RH ;

Bessen, LJ ;

Brosgart, C ;

DeGruttola, V ;

Mellors, JW .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :169-180

[8]

MEANS RE, 1997, J VIROL, V69, P5431

[9] Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies [J].

Race, E ;

Dam, E ;

Obry, V ;

Paulous, S ;

Clavel, F .

AIDS, 1999, 13 (15) :2061-2068

[10] Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors [J].

Schmidt, B ;

Korn, K ;

Moschik, B ;

Paatz, C ;

Überla, K ;

Walter, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3213-3216

← 1 2 →